Hepatitis B virus (HBV) DNA integration occurs during the reverse transcription process of HBV replication, which develops in the early stages of HBV infection and accompanies the entire disease course. The integration of HBV DNA is detrimental to the attainment of clinical cure goals and also raises the risk of developing liver cancer. Theoretically, nucleos(t)ide analogs can reduce the synthesis of new double-stranded linear DNA, but there is no clearance function for hepatocytes that have already integrated HBV. Therefore, patients with serum HBV DNA-negative conversions still have the risk of developing liver cancer. As an immunomodulatory drug, interferon can not only inhibit viral replication but also inhibit or even eliminate existing clonally amplified hepatocytes carrying integrated HBV DNA fragments. However, there are currently few studies on the effects of nucleos(t)ide analogues and interferon therapy on HBV DNA integration. Thus, large-scale clinical studies are urgently needed for further clarification.
乙型肝炎病毒（HBV）DNA整合发生于HBV复制的逆转录过程中，在HBV感染的早期即已发生并伴随整个病程。整合HBV DNA不利于临床治愈目标的达成，亦增加了发生肝癌的风险。理论上，核苷（酸）类似物可以减少新双链线性DNA合成，但对已存在HBV整合的肝细胞无清除功能，故血清HBV DNA阴转的患者仍存在发展为肝癌的风险；而干扰素作为一种免疫调节药物，不仅可以抑制病毒复制，还可以抑制甚至清除既存的携带整合HBV DNA片段的克隆性扩增肝细胞。然而，目前核苷（酸）类似物与干扰素治疗对HBV DNA整合影响的研究尚少，亟需开展大样本的的临床研究来进一步明确。.
Keywords: Clinical cure; DNA integration; Hepatitis B virus; Hepatocellular carcinoma; Interferon; Nucleos(t)ide-analogues.